Evidence map›Paper›PMID 22435680›Full record

ReviewEuropean journal of clinical investigation2012

Regenerative pulmonary medicine: potential and promise, pitfalls and challenges.

Piero Anversa, Mark A Perrella, Stella Kourembanas, Augustine M K Choi, Joseph Loscalzo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Cell-based therapy in lung regenerative medicine.Regenerative medicine research · 2014
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension.Revista brasileira de cirurgia cardiovascular : orgao oficial da Sociedade Brasileira de Cirurgia Cardiovascular
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Piero AnversaBrigham and Women's Hospital Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Mark A Perrella
Stella Kourembanas
Augustine M K Choi
Joseph Loscalzo

Funding

Tissue AnalysesP01HL048743 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LIBBY, PETER · 1992 to 2014
$26.3M
Mesenchymal Stromal Cell Conditioning by Carbon MonoxideP01HL108801 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2015
$13.8M
Rebuilding the Failing HeartP01HL092868 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ANVERSA, PIERO · 2008 to 2013
$12.9M
Single Molecule Analysis of Sickle Erythrocyte Adhesion in Sickle Cell DiseaseU54HL070819 · NHLBI · BOSTON MEDICAL CENTER · PI LEOPOLD, JANE A · 2003 to 2011
$12.5M
HYPOXIC RESPONSES OF VASCULAR SMOOTH MUSCLER01HL055454 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI KOUREMBANAS, STELLA · 1996 to 2018
$6.7M
GPx-3 and Peroxide Flux in the Endothelial CellR37HL061795 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2007 to 2016
$4.3M
The Phathophenotype Landscape of Complex DiseaseU01HL108630 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2011 to 2014
$2.7M
Mesenchymal Stem Cells and Pulmonary HypertensionR01HL085446 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KOUREMBANAS, STELLA · 2007 to 2011
$2.1M
Cardiomyocyte Differentiation Regulates Cardiac FunctionR01HL102897 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI PERRELLA, MARK A · 2011 to 2014
$1.7M
PLATELET DERIVED REACTIVE OXYGEN SPECIES AND PLAQUER01HL061795 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 1998 to 2006
$1.6M
Targeted Delivery of Progenitor Cells to the LungP50HL107192 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHOI, AUGUSTINE M, LOSCALZO, JOSEPH · 2011 to 2012
$1.0M
NHLBI NIH HHS HL055454NHLBI NIH HHS HL085446NHLBI NIH HHS HL092868NHLBI NIH HHS HL102897NHLBI NIH HHS HL107192NHLBI NIH HHS HL108630NHLBI NIH HHS HL108801NHLBI NIH HHS HL48743NHLBI NIH HHS HL61795NHLBI NIH HHS HL70819NHLBI NIH HHS P01 HL048743NHLBI NIH HHS P01 HL092868NHLBI NIH HHS P01 HL108801NHLBI NIH HHS P50 HL107192NHLBI NIH HHS R01 HL055454NHLBI NIH HHS R01 HL061795NHLBI NIH HHS R01 HL085446NHLBI NIH HHS R01 HL102897NHLBI NIH HHS R37 HL061795NHLBI NIH HHS U01 HL108630NHLBI NIH HHS U54 HL070819
6 · The paper itself

Abstract

backgroundChronic lung diseases contribute significantly to the morbidity and mortality of the population. There are few effective treatments for many chronic lung diseases, and even fewer therapies that can arrest or reverse the progress of the disease.

designIn this review, we present the current state of regenerative therapies for the treatment of chronic lung diseases. We focus on endothelial progenitor cells, mesenchymal stem cells, and endogenous lung stem/progenitor cells; summarize the work to date in models of lung diseases for each of these therapies; and consider their potential benefits and risks as viable therapies for patients with lung diseases.

conclusionsCell-based regenerative therapies for lung diseases offer great promise, with preclinical studies suggesting that the next decade should provide the evidence necessary for their ultimate application to our therapeutic armamentarium.

Indexed as

Mesenchymal Stem CellsAdult Stem CellsAnimalsEndothelial CellsHumansHypertension, PulmonaryLung DiseasesLung InjuryMaleModels, AnimalPulmonary EmphysemaPulmonary MedicineRegenerative MedicineStem Cell Transplantation

Identifiers

PMID22435680
PMCPMC3513384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.